Protocol Ledger

NCT04372615 · Phase II · RECRUITING

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

Interventional Phase II clinical trial protocol NCT04372615 sponsored by University of Utah in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-03-30 Enrollment: 116 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04372615
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)116 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04372615
Protocol FieldVerified Registry Value
NCT IdentifierNCT04372615
Consolidated Lead SponsorUniversity of Utah
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment116 participants (ESTIMATED)
Registered Start Date2022-03-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for University of Utah Health / Huntsman across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI